Intranasal Application of Lactococcus lactis W136 Is Safe in Chronic Rhinosinusitis Patients With Previous Sinus Surgery

• Published in: Frontiers in cellular and infection microbiology Vol. 10; p. 440
• Main Authors: Endam, Leandra Mfuna, Alromaih, Saud, Gonzalez, Emmanuel, Madrenas, Joaquin, Cousineau, Benoit, Renteria, Axel E., Desrosiers, Martin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 12.10.2020
• Subjects: Cellular and Infection Microbiology; chronic rhinosinusitis (CRS); CRS treatment; Lactococcus lactis W136; probiotics; sinus irrigation; sinus microbiome; CRS treatment; chronic rhinosinusitis (CRS); Lactococcus lactis W136; refractory CRS; sinus irrigation; probiotics; sinus microbiome
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2020.00440

Modulation of the dysbiotic gut microbiome with "healthy" bacteria via a stool transplant or supplementation is increasingly practiced, however this approach has not been explored in the nasal passages. We wished to verify whether ( bacteria could be safely applied via irrigation to the nasal and sinus passages in individuals with chronic rhinosinusitis (CRS) with previous undergone endoscopic sinus surgery, and whether this was accompanied by bacterial community flora modification. Prospective open-label pilot trial of safety and feasibility. Academic tertiary hospital center. Twenty-four patients with CRS refractory to previous medical and surgical therapy received a 14-day course of BID sinus irrigations containing 1.2 × 10 CFU live . Patients were monitored for safety using questionnaire, sinus endoscopy, otoscopy, UPSIT-40 smell testing, and endoscopically-obtained conventional sinus culture and a swab for 16S microbiome profiling. All 24 patients receiving at least one treatment successfully completed treatment. probiotic treatment was safe, with no major adverse events or new infections. Treatment was associated with improvement in sinus symptoms, QOL, and mucosal scores, which remained improved during the subsequent 14-day observation period. Microbiome changes associated with treatment were limited to an increase of the pathobiont , a bacteria identified as potentially beneficial in the upper airways. Subgroup analysis suggested differences in microbiomes and responses for CRSsNP and CRSwNP phenotypes, but these did not attain significance. Intranasal irrigation of live bacteria to patients with refractory chronic rhinosinusitis was safe, and was associated with effects on symptoms, mucosal aspect and microbiome composition. Intranasal bacteria may thus find a role as a treatment strategy for CRS. www.ClinicalTrials.gov. identifier: NCT04048174.